Letters to the Editor

Mechanism-driven innovative drug development for primary Sjögren's disease: insights from global clinical trial landscapes

F. Wu¹, L.W. Dai², G. Wu³

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wuguolin28@zju.edu.cn

CER19272
2025 Vol.43, N°12
PI 2226, PF 2228
Letters to the Editor

Free to view
(click on article PDF icon to read the article)

PMID: 41410588 [PubMed]

Received: 02/09/2025
Accepted : 30/10/2025
In Press: 18/12/2025
Published: 18/12/2025